HBM Healthcare Investments AG has published its Quarterly Report as at 31 December 2025, presenting key figures for the first nine months of the 2025/2026 financial year. The company reported a quarterly profit of CHF 191 million, bringing the total profit for the nine-month period to CHF 286 million. The net asset value increased by 18% during this period, while the share price rose by nearly 30%. The report notes a remaining discount of just under 20%. Significant events include the sale of a majority stake in Swixx BioPharma, after which HBM Healthcare Investments retains an approximately 8% stake in Swixx BioPharma and a 25.1% investment in Swixx Healthcare, which was spun off in 2024. The combined value growth from Swixx BioPharma and Swixx Healthcare exceeded CHF 340 million. The company also reported a negative currency effect of CHF 43 million and a decrease in the value of the funds portfolio by CHF 18 million due to currency fluctuations. HBM Healthcare Investments also benefited from the acquisition of portfolio company Bluejay Therapeutics by Mirum Pharmaceuticals and made two new investments in private companies during the quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2264874_en), on January 23, 2026, and is solely responsible for the information contained therein.